The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

about

New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.

P2860

Q55367746-6E335CFC-5D75-40C2-98A8-2526B8EFE5CD

P2860

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q38825283

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

@en

type

Item

label

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

@en

prefLabel

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

@en

P1476

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer

@en

P2093

Asuncion Diaz-Serrano

http://www.w3.org/2001/XMLSchema#string

Maria C Riesco-Martinez

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Modes of resistance to anti-angiogenic therapy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

VEGF receptor signalling - in control of vascular function

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.

Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.

Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

P304

585-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14737140.2016.1182430

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rocío García-Carbonero

P577

2016-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27144874

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

about

P2860

P2860

The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921